Previous close | 0.7400 |
Open | 0.1300 |
Bid | 0.0000 |
Ask | 2.1300 |
Strike | 332.50 |
Expiry date | 2024-07-05 |
Day's range | 0.1300 - 0.1300 |
Contract range | N/A |
Volume | |
Open interest | 23 |
A renaissance is stirring in cholesterol treatment, and it could drive Merck, Novartis and other stocks higher, while delivering new choices for millions of patients.
A new study led by investigators of a Harvard-affiliated teaching hospital found that Novo Nordisk's (NVO) GLP-1 drugs Ozempic and Wegovy could be linked to rare cases of vision loss.
Key Insights Amgen's estimated fair value is US$537 based on 2 Stage Free Cash Flow to Equity Amgen's US$309 share...